Skip to content

JIVROSG-0808(RADPLAT Japan, maxillary carcinoma-II) Cisplatinum (CDDP) transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study

JIVROSG-0808(RADPLAT Japan, maxillary carcinoma-II) Cisplatinum (CDDP) transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study - JIVROSG-0808 CDDP transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009011
Enrollment
44
Registered
2012-10-01
Start date
2012-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

maxillary carcinoma

Interventions

Transarterial infusion of cisplatinum to feeding artery of maxillary carcinoma and irradiation to the same lesion.

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Maxillaruy carcinoma which was pathologically diagnosed as squamous cell carcinoma. Tumor stage is T3 or T4 based on UICC 7th edition. Selective angiography of feeding artery is feasible. Life expectancy is 8 weeks or more. Performance status (ECOG) is 1, 2 or 3. Function of major organs (e.g., cardiac function, renal function) are preserved. Informed concent is obtained from the patient.

Exclusion criteria

Exclusion criteria: In status of myelosuppression. Serious infectious lesion exists in head or neck region. Serious complications exist(interstitial pneumonia, uncontrolable diabetes, heart failure, renal dysfunction, liver dysfunction, etc). Viable double cancer or other malignant disease exists. Patients who have past history of radiation therapy to head and neck region. Patients who have allergic history for iodine contrast medium or platinums. Patients who have serious mental disorder.

Design outcomes

Primary

MeasureTime frame
local control rate

Secondary

MeasureTime frame
primary tumor response rate, frequency and grade of adverse event, 5 years survival rate and reurrence rate

Countries

Japan

Contacts

Public ContactNorimitsu Tanaka

Kurume University Department of Radiology

nori@med.kurume-u.ac.jp0942-31-7576

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026